Psychedelic Research and Access in
Algeria
Algeria presents a highly restrictive environment for psychoactive and hallucinogenic substances. The country's drugs law criminalises illicit use, possession and trafficking of narcotics and psychotropic substances, while allowing narrow medical or scientific authorisation pathways.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inAlgeria.
- 1
The legal regime is built around control and criminal enforcement, not therapeutic access.
- 2
Medical or scientific authorisation exists in principle, but the public sources do not show a routine psychedelic therapy pathway.
- 3
The absence of linked trials in Blossom is consistent with the lack of visible, public psychedelic research activity in Algeria.
- 4
Recent legislative signals suggest the drug law has been updated, but the exact impact on research access is not clear from the public summaries alone.
- 5
Ketamine or other controlled anaesthetic use may exist in medical practice, but that does not imply lawful access to classical psychedelics.
Research and Access Snapshot
Blossom currently keeps Algeria as a country profile, but no psychedelic clinical trials, stakeholders, or events are linked to this country yet.
Blossom has not linked country-level trial records yet. Treat this as a coverage gap, not proof that no local policy discussion, care, or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 0
- Events
- 0
None marked active
No linked trials
No linked stakeholders
No linked events
Top Compounds
Linked country trials do not show a leading compound yet.
Top Study Topics
Linked country trials do not show a leading study topic yet.
Medical Access
Algeria maintains a prohibitionist, tightly regulated regime for psychoactive/hallucinogenic substances: national narcotics and psychotropes law explicitly criminalises trafficking, possession and use (with narrow medical/scientific exemptions) while the health system uses certain controlled substances (notably ketamine) for approved medical/anesthetic purposes. There is no established, reimbursed clinical program for classical psychedelic therapies (psilocybin, MDMA, mescaline, DMT, 5-MeO-DMT, ibogaine, ayahuasca, 2C-X) outside of specially authorised...
Regulatory Status
Algeria's framework is prohibitionist: Law No. 04-18 criminalises illicit use and traffic in narcotics and psychotropic substances, while official legislative summaries indicate authorisations are only possible for medical or scientific purposes. A recent official ONLCDT legislative page also shows the law was amended in 2023, and an UNODC/CND Algeria presentation in 2025 refers to further amendments in 2025, so the current detail should be treated with some caution pending review of the latest consolidated text. Based on the available sources, classical psychedelic medicines do not appear to have a general lawful access pathway outside specially authorised medical/scientific activity.
Country Details
- Region
- Africa
- Last updated
- 4 May 2026
Country Report
Strictly IllegalMedical Access
Algeria maintains a prohibitionist, tightly regulated regime for psychoactive/hallucinogenic substances: national narcotics and psychotropes law explicitly criminalises trafficking, possession and use (with narrow medical/scientific exemptions) while the health system uses certain controlled...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for Algeria.
Open scorecard →